Radiotherapy Trials
| ClinicalTrials.gov Identifier: |
NCT04170946 |
This study is currently recruiting participants
This is a phase I, dose escalating study evaluating the safety of combining talazoparib and low dose consolidative thoracic radiotherapy for small cell lung cancer patients. This study will also determine the maximum tolerated dose (MTD) of talazoparib in combination with low dose thoracic radiotherapy.
Patients will start on talazoparib on day 1 of study intervention, and will continue to orally take talazoparib until the last day of radiation therapy. Up to 24 patients will be enrolled to the study, where the first 3 patients will start with a starting dose level of talazoparib is 0.5 mg PO once daily. This will increase to 1mg daily with each new cohort.
Ontario
Princess Margaret Hospital, Toronto
| ClinicalTrials.gov Identifier: |
NCT01803542 |
This study is currently recruiting participants
The purpose of this institutional protocol is to offer SBRT to selected patients in a controlled environment to refine treatment techniques (including dose/fractionation schedules) and standardize follow-up.
Ontario
Princess Margaret Hospital, University Health Network, Toronto
| ClinicalTrials.gov Identifier: |
NCT03705806 |
This study is currently recruiting participants
The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
Ontario
University Health Network, Princess Margaret Cancer Centre
| ClinicalTrials.gov Identifier: |
NCT02788461 |
This study is currently recruiting participants
A randomized phase II trial to assess the efficacy and safety of selective metabolically adaptive radiation dose escalation in locally advanced non-small cell lung cancer receiving definitive chemoradiotherapy. Eligible and consenting patients will be randomized to receive conventional chemoradiotherapy or chemoradiotherapy with a radiation (RT) integrated boost. All patients will receive a fludeoxyglucose-positron emission tomography (FDG-PET) scan within two weeks prior to starting treatment. The primary outcome is to determine if dose escalation to metabolically active tumour subvolumes will reduce local-regional failure rate at 2 years.
Ontario
London Regional Cancer Program, London
Princess Margaret Cancer Centre, Toronto
| ClinicalTrials.gov Identifier: |
NCT02468024 |
This study is currently recruiting participants
JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial.
Quebec
CHUM,
Montréal, 26214
Ontario
Trillium Health Partners
Ottawa Hospital, Ottawa
University Health Network, Toronto
Sunnybrook Health Sciences Centre, Toronto
| ClinicalTrials.gov Identifier: |
NCT03322072 |
This study is currently recruiting participants
This is a single arm seamless phase I/II prospective cohort study. Patients with early stage Non-Small Cell Lung Cancer (T1-T2N0M0) or those with a single pulmonary metastasis of a known malignancy (either following radical treatment or systemic therapy) will be offered participation in this study. Participants will have three tumor locator beacons placed with a flexible bronchoscope in the small bronchial airways in proximity (<3cm) from their lung tumors. These tumor locator beacons will provide real-time positional data and will allow for smaller treatment volumes of Stereotactic Ablative Radiosurgery (SABR) and also allow for a specialized form of treatment delivery known as respiratory gated SABR. This is expected to result in higher precision radiotherapy delivery with less radiotherapy dose to healthy tissues which are in close proximity to the lung tumours.
Manitoba
CancerCare Manitoba, Winnipeg
| ClinicalTrials.gov Identifier: |
NCT03833154 |
This study is currently recruiting participants
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.
Alberta
Calgary
Edmonton
Ontario
London
Toronto
Quebec
Montreal
| ClinicalTrials.gov Identifier: |
NCT03924869 |
This study is active, but not recruiting participants
The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).
New Brunswick
Moncton
Ontario
Kingston
Mississauga
Ottawa
Sault Ste. Marie
Sudbury
Quebec
Montreal, QC
Sherbrooke, QC
| ClinicalTrials.gov Identifier: |
NCT00797719 |
This study is active but not recruiting participants
A Feasibility Study Evaluating Neoadjuvant Hemithoracic Intensity Modulated Radiation Therapy for Surgically Resectable Malignant Pleural Mesothelioma.
Ontario
University Health Network, Toronto
| ClinicalTrials.gov Identifier: |
NCT01279408 |
This study is active, but not recruiting participants
The aim of the study is to assess current practice within PROP &lung teams, for treating asymptomatic patients with centrally located non-small cell lung cancer (NSCLC), and to observe outcomes for those patients receiving immediate or deferred RT. This is a prospective cohort trial. Patients will be managed by immediate radiotherapy (RT) or a deferred approach according to physicians' individual current clinical practice.
Ontario
University Health Network, Toronto
| ClinicalTrials.gov Identifier: |
NCT02756793 |
This study is currently active but not recruiting participants
A multicenter randomized phase II trial of stereotactic body radiotherapy for oligo-progressive non-small cell lung cancer. Eligible patients will be randomized in a 1:2 ratio between receiving their standard of care therapy or stereotactic ablative radiotherapy (SABR) to all sites of oligo-progressive lesions. Radiotherapy will be administered as soon as possible following randomization, and subjects will be followed until next disease progression. The primary outcome is progression-free survival (PFS).
British Columbia
BC Cancer Agency Fraser Valley, Surrey
Ontario
London Regional Cancer Program, London
| ClinicalTrials.gov Identifier: |
NCT02635009 |
This study is active but not recruiting participants
This randomized phase II/III trial studies how well whole-brain radiation therapy works and compares it with or without hippocampal avoidance in treating patients with small cell lung cancer that is found in one lung, the tissues between the lungs, and nearby lymph nodes only (limited stage) or has spread outside of the lung in which it began or to other parts of the body (extensive stage). Radiation therapy uses high energy x-rays to kill tumour cells and shrink tumours. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It is not yet known whether giving whole-brain radiation therapy is more effective with or without hippocampal avoidance in treating patients with small cell lung cancer.
Quebec
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), Quebec City
| ClinicalTrials.gov Identifier: |
NCT02973789 |
This study is active, but not recruiting participants
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
Quebec
McGill University Health Centre
Montréal, QC, H4A 3J1
Contact: Nicola Raby, 514-934-1934 ext. 34095
[email protected]
Principal Investigator: Scott Owen, MD
Centre intégré universitaire de santé et de services sociaux de l'Estrie –
Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS)
Sherbrooke, QC, J1H 5N4
Contact: Anick Champoux, RN
819-346-1110 ext. 12811
[email protected]
Principal Investigator: Nicole Bouchard, MD
Saskatchewan
Allan Blair Cancer Center
Regina, SK, S4T 7T1
Contact: Wendie Templeton, CCRP
306-766-2488
[email protected]
Principal Investigator: Mussawar Iqbal, MD
| ClinicalTrials.gov Identifier: |
NCT03306680 |
This study is active, but not recruiting participants
This multi-centre phase I dose-escalation study will use a time-to-event continual reassessment method (TIT-CRM).
Accrual will start at level 1 (60 Gy in 8 fractions). Patients will be assigned to treatment doses using the TITE-CRM model. The model will use all available information from previously accrued patients to assign the highest dose with a predicted risk of grade 3 toxicity of 30% or less.
British Columbia
BC Cancer -Vancouver Island
Ontario
London Regional Cancer Program
Princess Margaret Cancer Centre
Quebec
Centre Hospitalier de l'Universite de Montreal (CHUM)
McGill University Health Centre-Cedars Cancer Centre
Saskatchewan
Saskatoon Cancer Centre